Wexford Capital's exit below the 5% threshold removes a long-standing activist overhang but signals a lack of conviction in near-term value creation. Monitor for any further insider selling and whether new activist investors emerge to fill the void.
Price Chart
Executive Summary
Wexford Capital LP filed Amendment No. 12 to its Schedule 13D on Nephros, reporting that it ceased to be the beneficial owner of more than 5% of the common stock as of September 14, 2026. The filing describes an in-kind distribution of shares to underlying investors and a sale of shares to an entity controlled by director Arthur Amron, with no additional consideration received by the distributing entities. This represents a significant de-escalation by the activist, reducing its stake below the 5% reporting threshold.
Key Financial Metrics
Key Facts
- Wexford Capital LP ceased to be the beneficial owner of more than 5% of Nephros common stock on September 14, 2026.
- The filing reports 223,539 shares beneficially owned, representing 2.06% of the 10,860,120 shares outstanding as of August 7, 2026.
- The reduction was effected via an in-kind distribution of shares to underlying investors and a sale of shares to an entity controlled by director Arthur Amron.
- No distributing entities received any compensation in connection with the transaction.
- This is Amendment No. 12 to the initial Schedule 13D filed on October 1, 2007.
Financial Impact
Wexford Capital reduced its stake from above 5% to 2.06%, distributing/selling a substantial block of shares. The exact number of shares distributed/sold is not specified beyond the remaining 223,539 shares.
Risk Factors
- Loss of activist pressure could reduce management accountability and strategic urgency.
- The large distribution/sale may have created overhang that pressured the stock, and further selling could continue.
- The company's small market cap and low liquidity amplify the impact of any future block sales.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001398344-26-017130 |
| Document: 0001398344-26-017130-index.html | 0001398344-26-017130 |
| Document: 0001398344-26-017130.txt | 0001398344-26-017130 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | DEF 14A | $3.51 | awaiting T+20 | — | $3.63 (+3.42%) |
Oct 13, 2026 13d ago | 8-K | $3.52 | awaiting T+20 | — | $3.63 (+3.13%) |
Sep 16, 2026 5w ago | SC 13D/A | $4.23 $3.51 | ▲ +17.02% | ▲ +18.23% | $3.63 (+14.18%) |
Sep 16, 2026 5w ago | SC 13G | $4.23 $3.51 | ▼ −17.02% | ▼ −18.23% | $3.63 (−14.18%) |
Aug 6, 2026 11w ago | 8-K | $4.21 $4.06 | ▼ −3.56% | ▼ −3.17% | $3.63 (−13.78%) |
May 7, 2026 24w ago | 8-K | $3.52 $3.42 | ▼ −2.84% | ▼ −2.86% | $3.63 (+3.13%) |
Apr 30, 2026 25w ago | Press Release | $3.11 $3.69 | ▲ +18.65% | ▲ +13.38% | $3.63 (+16.72%) |
Mar 12, 2026 32w ago | Press Release | $3.50 $2.91 | ▼ −16.86% | ▼ −20.45% | $3.63 (+3.71%) |
Mar 5, 2026 33w ago | Press Release | $3.89 $2.87 | ▼ −26.22% | ▼ −22.43% | $3.63 (−6.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers